A blistering disease: bullous erysipelas.
Edwards
Janet
J
Division of Dermatology, Dalhousie University, Halifax, NS.
Green
Peter
P
Haase
David
D
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001768:Blister / Q000188:drug therapy* / Q000209:etiology; D002437:Cefazolin / Q000627:therapeutic use; D002481:Cellulitis / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004886:Erysipelas / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011339:Probenecid / Q000627:therapeutic use; D014528:Uricosuric Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014528:Uricosuric Agents; D002437:Cefazolin; D011339:Probenecid